Welcome to our dedicated page for ICF International news (Ticker: $ICFI), a resource for investors and traders seeking the latest updates and insights on ICF International stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ICF International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ICF International's position in the market.
ICF has been awarded a $236 million contract by USAID to continue delivering their Demographic and Health Surveys Program, known as the 'gold standard' of health surveys. The contract aims to improve health outcomes by providing critical data for population, health, and nutrition programs worldwide. ICF's approach includes strengthening countries' capacity to collect and analyze data, incorporating technology and AI for efficiency, and focusing on vulnerable populations. The company's work spans various global health and development initiatives.
ICF (NASDAQ: ICFI) reported record first quarter results for 2024, with revenues up 2% to $494 million, net income of $27 million, and GAAP EPS of $1.44. Non-GAAP EPS increased to $1.77, and contract awards were $495 million, up 21% year-on-year. The company reaffirmed full-year guidance and expects organic revenue growth of 5.2% to 8.5% for 2024.
